Among 48 randomized studies covering eight classes of antihyperglycemic treatments and reporting stroke outcomes, only GLP-1 receptor agonists and thiazolidinediones exhibited statistically significant reductions in stroke occurrences [36]. SGLT-2 inhibitors were found to reduce kidney endpoints, hospitalizations for heart failure, and the composite of MACEs across various patients with T2DM; however, they did not demonstrate a reduction in stroke incidence [35,36]. The gene discussed is SLC5A2; the disease is heart failure.